1. 282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. (23rd October 2018) Authors: Fasching, P A; Decker, T; Guderian, G; Heim, J; Jackisch, C; Lueck, H-J; Lüftner, D; Marmé, F; Reimer, T; Woeckel, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗